Mundipharma, a global pharma network, has announced that laboratory testing at the Duke-NUS Medical School in Singapore confirmed the effectiveness of its BETADINE antiseptic products against the SARS-CoV-2 that causes COVID-19 disease, it was reported on Thursday.
Testing indicated that the product's in-vitro virucidal activity kills 99.99% of the virus in 30 seconds.
Another Laboratory testing completed at the Tropical Infectious Diseases Research and Education Center at the University of Malaya, Malaysia, also indicated strong in-vitro virucidal activity, with the tested product BETADINE Gargle and Mouthwash (1.0-% PVP-I) killing 99.99% of the SARS-CoV-2 virus in 15 seconds. The BETADINE antiseptic range includes Povidone-iodine.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA